Role of Alprazolam in the Management of Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-25

Study Completion Date

2022-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adrenaline for the Treatment of No-Reflow in Normotensive Patients

NCT04699110

Acute Coronary Syndrome No-Reflow Phenomenon Normotensive

COMPLETED PHASE4

Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

NCT00549614

Heart Failure

COMPLETED NA

Beta-Blocker Heart Attack Trial (BHAT)

NCT00000492

Arrhythmia Cardiovascular Diseases Coronary Disease +5 more

COMPLETED PHASE3

Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar

NCT02648243

Acute Coronary Syndromes

COMPLETED NA

Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI

NCT07138508

No Reflow Phenomenon Anterior STEMI

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to chest pain and hospital admission causing tachycardia. This study is designed to achieve the goals of lowering the heart using the anxiolytic property of alprazolam. This randomized, parallel group, close label, placebo-controlled, event driven, interventional clinical superiority study will be conducted in Cardiology department of Shaikh Zayed Hospital with a sample size of 48 allocating using lottery method in both experimental and control group. Heart Rate at baseline and after 6 hours will be monitored in both groups to establish the fall of heart rate in both patients. Data will be collected by using pre-designed performa and will be entered and analyzed via SAS 9.4. Statistical analysis will be done using T-test and p value \<0.05 will be considered significant.

Significance of the study is to lower the required dosage of beta-blockers in order to achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome Myocardial Infarction ST Elevation Myocardial Infarction Heart Diseases Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This randomized, close label, placebo-controlled study with superiority framework as add-on therapy in ACS patients

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Masking will be done for all participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alprazolam Arm

0.5mg Alprazolam will be given to the patient at the time of presentation

Group Type EXPERIMENTAL

Alprazolam

Intervention Type DRUG

Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency

Placebo Arm

The empty capsule will be given to the patient at the time of presentation

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Empty capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alprazolam

Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency

Intervention Type DRUG

Placebo

Empty capsule

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Systolic BP\>100mm Hg Age between 18-80 years Sinus Rhythm

Exclusion Criteria

* Cardiogenic Shock / Hypotension
* Known Asthma/COPD
* Bradycardia (HR \< 60)
* Already on Beta blockers/ Anxiolytics
* Sick sinus syndrome
* Second or third-degree heart block (in the absence of pacemaker)
* Decompensated heart failure
* With documented hypersensitivity to the drug or components
* Valvular Heart Diseases
* Congenital Heart Diseases
* Status post CABG
* Any co-morbidities except Diabetes Mellitus and Hypertension

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No